Cost-effectiveness of Targeted Human Immunodeficiency Virus Screening in an Urban Emergency Department

被引:21
作者
Dowdy, David W. [1 ]
Rodriguez, Robert M. [2 ,4 ]
Hare, C. Bradley [3 ]
Kaplan, Beth [2 ,4 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA USA
[3] Univ Calif San Francisco, Posit Hlth Program, San Francisco, CA USA
[4] San Francisco Gen Hosp, Dept Emergency Serv, San Francisco, CA 94110 USA
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HIV PREVENTION PROGRAMS; QUALITY-OF-LIFE; UNITED-STATES; SEXUAL TRANSMISSION; PERSONS AWARE; VIRAL LOAD; INFECTION; RECOMMENDATIONS; METAANALYSIS;
D O I
10.1111/j.1553-2712.2011.01110.x
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Although targeted screening of patients at high risk for human immunodeficiency virus (HIV) infection in the emergency department (ED) improves patient outcomes and may prevent HIV transmission, ED-based screening programs incur additional costs and have thus not been widely scaled up. The objective of this study was to evaluate the cost-effectiveness of ED-based targeted HIV screening as implemented in actual practice. Methods: This was a cost-utility analysis of a rapid HIV screening program in an urban ED. Physicians were encouraged to screen patients undergoing inpatient admission or who had HIV risk factors. The authors measured costs directly and estimated quality-adjusted life expectancy using chart review, literature assumptions, and mathematical modeling. Incremental cost utility was evaluated from a societal perspective using a lifetime time horizon. Results: From June 2008 through September 2009, a total of 3,766 HIV tests were ordered (235 tests per month), of which an estimated 2,406 (64%) represented screening in patients without HIV-related signs or symptoms. Nineteen (0.8%) patients were newly diagnosed through screening during the study period, of whom nine (47%) were eligible for antiretroviral therapy (ART) and maintained consistent outpatient follow-up. Estimated screening costs were $82,300 per year, or $45.53 per screening test, of which $28.01 (62%) was for program management. Targeted screening prevented an estimated 2.1 HIV transmission events over 16 months. Per patient screened, targeted screening saved $112 (95% uncertainty range [UR] = $20 to $225) and resulted in 2.71 quality-adjusted life-days gained (95% UR = 1.71 to 4.01). Cost-utility was most sensitive to the prevalence of undiagnosed HIV in the screened population. Conclusions: Targeted HIV screening, as implemented in an urban ED, is cost saving and increases quality-adjusted life expectancy. ACADEMIC EMERGENCY MEDICINE 2011; 18: 745-753 (C) 2011 by the Society for Academic Emergency Medicine
引用
收藏
页码:745 / 753
页数:9
相关论文
共 44 条
[1]  
[Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
[2]  
*ASS ADV COST ENG, PAR COST EST MOD BUI
[3]   Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis [J].
Attia, Suzanna ;
Egger, Matthias ;
Mueller, Monika ;
Zwahlen, Marcel ;
Low, Nicola .
AIDS, 2009, 23 (11) :1397-1404
[4]   Opt-out testing for human immunodeficiency virus in the United States - Progress and challenges [J].
Bartlett, John G. ;
Branson, Bernard M. ;
Fenton, Kevin ;
Hauschild, Benjamin C. ;
Miller, Veronica ;
Mayer, Kenneth H. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (08) :945-951
[5]   What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule? [J].
Braithwaite, R. Scott ;
Meltzer, David O. ;
King, Joseph T., Jr. ;
Leslie, Douglas ;
Roberts, Mark S. .
MEDICAL CARE, 2008, 46 (04) :349-356
[6]   Undiagnosed HIV Prevalence Among Adults and Adolescents in the United States at the End of 2006 [J].
Campsmith, Michael L. ;
Rhodes, Philip H. ;
Hall, H. Irene ;
Green, Timothy A. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (05) :619-624
[7]  
*CDCP, 2007, HIV AIDS SURV REP, V19
[8]  
Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, pRR
[9]  
Centers for Disease Control and Prevention, FDA APPR RAP HIV ANT
[10]  
*COL, MEG 11R PROD DET DIS